Last checked at 
(Alliance News) - Biotechnology company Destiny Pharma PLC on Monday announced the appointment of Debra Barker as an independent non-executive director from the start of 2020.
Barker is currently on the board of Hutman Diagnostics, a molecular diagnostic company specialising in antimicrobial resistance, and BerGenBio, an oncology company targeting immune-evasive and therapy resistance cancers.
She was previously the chief medical & development officer at Swiss pharmaceutical company Polyphor AG.
Nick Rodgers, chair of Destiny Pharma, said: "We are delighted to announce Barker's appointment to the Destiny board. Debra has significant experience of late stage drug development, including anti-infectives and a long-standing interest in microbiology and infection management in a clinical setting. Barker also has broader corporate experience of in-licencing and portfolio development."
Shares in Brighton-based Destiny Pharma were down 0.6% at 41.25 pence on Monday in London.
By Ife Taiwo; ifetaiwo@alliancenews.com
Copyright 2019 Alliance News Limited. All Rights Reserved.
